Presented by Dr. Carl J. Lavie, MD

Description: During this presentation, Dr. Lavie will review the adverse effects of obesity and cardiovascular disease risk factors and to increase the prevalence of cardiovascular disease. He will discuss the main factors that increase obesity in the first place, including fast foods, sugary beverages, but especially the progressive fall in physical activity over 5 decades. This presentation will define the obesity paradox and how this is impacted by physical activity and fitness and will describe the increase in cardiometabolic diseases associated with obesity and potential benefits of cardiac rehabilitation.

Learning Objectives:

1. Describe the adverse effects of obesity to increase CVD risk factors and prevalence of CVD.
2. Summarize the obesity paradox and how this is impacted by physical activity and fitness.
3. Describe the increase in cardiometabolic diseases and potential benefits of cardiac rehabilitation.

Recordings will be made available within 10 business days following each webinar. There is a 60-day viewing window for the recordings. This presentation series is sponsored by Novo Nordisk, Inc. This presentation is not offered for credits (CEUs).

Presented by Megan Hays, PhD, ABPP, FAACVPR

Description: This webinar will explore the complex relationship between obesity, behavior change, and cardiovascular health, equipping multidisciplinary cardiac and pulmonary rehabilitation professionals with strategies to enhance patient care. Dr. Megan Hays will discuss social determinants of health, weight bias, gut-brain connections, and the psychological impact of obesity, providing insights into overcoming exercise apprehension and improving adherence. Attendees will gain practical tools to support behavior change, reduce cardiovascular risk, and foster a more inclusive, patient-centered rehabilitation experience. Join us for this essential discussion on empowering patients in their journey to better heart health.

Learning Objectives: 

1. Clarify the contributions of social determinants of health, weight bias, and various behaviors to body weight.
2. Learn evidence-based practical approaches to address exercise apprehension, enhance adherence, and support sustainable lifestyle modifications to improve cardiovascular well-being.
3. Develop strategies to provide sensitive, patient-centered care for individuals with obesity, ensuring a supportive rehabilitation environment that promotes long-term cardiovascular health.

Recordings will be made available within 10 business days following each webinar. There is a 60-day viewing window for the recordings. This presentation series is sponsored by Novo Nordisk, Inc. This presentation is not offered for credits (CEUs).

Presented by Tracey H. Taveira, Pharm.D., CDOE, CVDOE

Description: This continuing education program focuses on advancing the understanding and management of obesity and associated cardiovascular risks. Participants will review the latest literature, emphasizing the role of GLP-1 receptor agonists in reducing major adverse cardiovascular events (MACE). The program will also explore the comparative effectiveness of novel obesity treatments, such as GLP-1 and GLP-1/GIP receptor agonists, against traditional weight loss medications. Additionally, attendees will gain practical insights into improving medication adherence by addressing common barriers, fostering effective patient provider communication, and implementing strategies to manage side effects and optimize medication tolerance. This overarching goal is to enhance clinical outcomes and support evidence-based practice in obesity care.

Learning Objectives: 

1. Review current guidelines and literature on the management of obesity and cardiovascular risk, with a focus on the use of GLP-1 receptor agonists to reduce major adverse cardiovascular events (MACE).
2. Compare outcomes of novel obesity treatments, including GLP-1 and GLP-1/GIP receptor agonists, against previously available medications for weight loss.
3. Develop strategies to improve medication adherence by understanding common barriers, promoting patient-provider communication, and implementing tips to manage side effects and optimize medication tolerance.

Recordings will be made available within 10 business days following each webinar. There is a 60-day viewing window for the recordings. This presentation series is sponsored by Novo Nordisk Inc. No credits (CEUs) are available for this free webinar series.